Browsing by Author "West, Andrew B"
- Results Per Page
- Sort Options
Item Open Access Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites.(Acta neuropathologica, 2021-05) Tokarew, Jacqueline M; El-Kodsi, Daniel N; Lengacher, Nathalie A; Fehr, Travis K; Nguyen, Angela P; Shutinoski, Bojan; O'Nuallain, Brian; Jin, Ming; Khan, Jasmine M; Ng, Andy CH; Li, Juan; Jiang, Qiubo; Zhang, Mei; Wang, Liqun; Sengupta, Rajib; Barber, Kathryn R; Tran, An; Im, Doo Soon; Callaghan, Steve; Park, David S; Zandee, Stephanie; Dong, Xiajun; Scherzer, Clemens R; Prat, Alexandre; Tsai, Eve C; Takanashi, Masashi; Hattori, Nobutaka; Chan, Jennifer A; Zecca, Luigi; West, Andrew B; Holmgren, Arne; Puente, Lawrence; Shaw, Gary S; Toth, Gergely; Woulfe, John M; Taylor, Peggy; Tomlinson, Julianna J; Schlossmacher, Michael GThe mechanisms by which parkin protects the adult human brain from Parkinson disease remain incompletely understood. We hypothesized that parkin cysteines participate in redox reactions and that these are reflected in its posttranslational modifications. We found that in post mortem human brain, including in the Substantia nigra, parkin is largely insoluble after age 40 years; this transition is linked to its oxidation, such as at residues Cys95 and Cys253. In mice, oxidative stress induces posttranslational modifications of parkin cysteines that lower its solubility in vivo. Similarly, oxidation of recombinant parkin by hydrogen peroxide (H2O2) promotes its insolubility and aggregate formation, and in exchange leads to the reduction of H2O2. This thiol-based redox activity is diminished by parkin point mutants, e.g., p.C431F and p.G328E. In prkn-null mice, H2O2 levels are increased under oxidative stress conditions, such as acutely by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxin exposure or chronically due to a second, genetic hit; H2O2 levels are also significantly increased in parkin-deficient human brain. In dopamine toxicity studies, wild-type parkin, but not disease-linked mutants, protects human dopaminergic cells, in part through lowering H2O2. Parkin also neutralizes reactive, electrophilic dopamine metabolites via adduct formation, which occurs foremost at the primate-specific residue Cys95. Further, wild-type but not p.C95A-mutant parkin augments melanin formation in vitro. By probing sections of adult, human midbrain from control individuals with epitope-mapped, monoclonal antibodies, we found specific and robust parkin reactivity that co-localizes with neuromelanin pigment, frequently within LAMP-3/CD63+ lysosomes. We conclude that oxidative modifications of parkin cysteines are associated with protective outcomes, which include the reduction of H2O2, conjugation of reactive dopamine metabolites, sequestration of radicals within insoluble aggregates, and increased melanin formation. The loss of these complementary redox effects may augment oxidative stress during ageing in dopamine-producing cells of mutant PRKN allele carriers, thereby enhancing the risk of Parkinson's-linked neurodegeneration.Item Open Access Genetics and genomics of LRRK2 linked-disease(2022) Bryant, NicoleGenetic variants in Leucine Rich Repeat Kinase 2 (LRRK2) are implicated in multiple diseases, most notably Parkinson’s disease (PD). These variants range in effect from protecting from disease to causing disease. Of the thousands of possible disease-associated genetic variants in the LRRK2 gene, function has only been assigned to a few. Exploiting new functional and bioinformatic approaches, herein, we developed an unbiased pipeline working from the genetic variant back to function, rather than starting with disease status and working back to a candidate variant. We interrogated thousands of missense variants for potential to impact LRRK2 function from both a PD-enriched cohort and broader non-disease related cohort utilizing the combinatorial, computational prediction tool REVEL tailored to predict classifications of rare missense variants. Using newly minted whole-genome sequencing libraries, we identified hundreds of novel LRRK2 variants across a range of ethnicities with high probability of damaging LRRK2-protein function. We performed structural modeling to predict outcome of the altered function of the missense variant on LRRK2 function, and identified top candidates to evaluate biochemically. Additionally, we identified two novel LRRK2 haplotypes with important implications in PD. These findings anchored on two novel assays that were developed to further investigate LRRK2 protein function and intricacies of variant-driven alterations. The first, a high-throughput biomarker-based assay to screen novel LRRK2 variants for functional impact, and the second, a proximity-labeling proteomics assay to uncover network changes associated with functional genetic variation. We developed three novel single-molecule immunoassays (SiMoA) on the Quanterix SR-X platform to evaluate LRRK2 variant functional consequences, particularly centered around the trans-phosphorylation of pT73-Rab10. We also screened our novel variant candidates for another main readout of LRRK2 enzymatic function, autophosphorylation of pS1292-LRRK2. We identified novel variants in LRRK2 that impact kinase function in one or both of the biochemical screens. Collectively, we observed that these two LRRK2 kinase events do not correlate with one another and have the potential to be uncoupled in the context of some LRRK2 coding variants. We also tested our novel SiMoA assays for use in a biomarker context by evaluating them across various biological sample matrices including rodent serum, and human cerebrospinal fluid and urine. The second proximity-labeling proteomics approach was adapted from a previous publication, modified for LRRK2 fusion and optimized for quantitative assessment of LRRK2 proximity network changes under various conditions of the enzyme. Herein we used the ascorbate peroxidase (APEX2) proximity labeling enzyme fused to our protein of interest, LRRK2. We performed appropriate quality control experiments and optimized the labeling and lysate processing approaches to improve the yield and reduce variability of the mass spectrometry results. We tested our APEX2-LRRK2 proximity-labeling fusion construct across a spectrum of LRRK2 kinase functional states: basal, pharmacological kinase inhibition and genetic activation states in vitro. We found that the active conformation of LRRK2 may be the most important in determining proximity networks independent of LRRK2s ability to phosphorylate. In all we developed a novel LRRK2 proximity-labeling tool optimized for quantitative experimental readouts. As LRRK2-targeted therapies enter efficacy stages in clinical trials, the identification of novel variant carriers that could benefit from LRRK2-targeted therapeutics combined with new efficacious biomarker strategies could be transformative to enhance precision approaches in genetically-defined disease. Moreover, the impacts of novel variants on kinase function combined with advanced proteomic evidence surrounding the molecular function of LRRK2 and disruptions that arise in disease states will be crucial in better understanding LRRK2’s typical function and role in disease pathogenesis.
Item Open Access Proteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease.(EBioMedicine, 2019-07) Wang, Shijie; Kojima, Kyoko; Mobley, James A; West, Andrew BBACKGROUND:Extracellular vesicles (EVs) harbor thousands of proteins that hold promise for biomarker development. Usually difficult to purify, EVs in urine are relatively easily obtained and have demonstrated efficacy for kidney disease prediction. Herein, we further characterize the proteome of urinary EVs to explore the potential for biomarkers unrelated to kidney dysfunction, focusing on Parkinson's disease (PD). METHODS:Using a quantitative mass spectrometry approach, we measured urinary EV proteins from a discovery cohort of 50 subjects. EVs in urine were classified into subgroups and EV proteins were ranked by abundance and variability over time. Enriched pathways and ontologies in stable EV proteins were identified and proteins that predict PD were further measured in a cohort of 108 subjects. FINDINGS:Hundreds of commonly expressed urinary EV proteins with stable expression over time were distinguished from proteins with high variability. Bioinformatic analyses reveal a striking enrichment of endolysosomal proteins linked to Parkinson's, Alzheimer's, and Huntington's disease. Tissue and biofluid enrichment analyses show broad representation of EVs from across the body without bias towards kidney or urine proteins. Among the proteins linked to neurological diseases, SNAP23 and calbindin were the most elevated in PD cases with 86% prediction success for disease diagnosis in the discovery cohort and 76% prediction success in the replication cohort. INTERPRETATION:Urinary EVs are an underutilized but highly accessible resource for biomarker discovery with particular promise for neurological diseases like PD.Item Open Access The interplay between monocytes, α-synuclein and LRRK2 in Parkinson's disease.(Biochemical Society transactions, 2023-04) Strader, Samuel; West, Andrew BThe accumulation of aggregated α-synuclein in susceptible neurons in the brain, together with robust activation of nearby myeloid cells, are pathological hallmarks of Parkinson's disease (PD). While microglia represent the dominant type of myeloid cell in the brain, recent genetic and whole-transcriptomic studies have implicated another type of myeloid cell, bone-marrow derived monocytes, in disease risk and progression. Monocytes in circulation harbor high concentrations of the PD-linked enzyme leucine-rich repeat kinase 2 (LRRK2) and respond to both intracellular and extracellular aggregated α-synuclein with a variety of strong pro-inflammatory responses. This review highlights recent findings from studies that functionally characterize monocytes in PD patients, monocytes that infiltrate into cerebrospinal fluid, and emerging analyses of whole myeloid cell populations in the PD-affected brain that include monocyte populations. Central controversies discussed include the relative contribution of monocytes acting in the periphery from those that might engraft in the brain to modify disease risk and progression. We conclude that further investigation into monocyte pathways and responses in PD, especially the discovery of additional markers, transcriptomic signatures, and functional classifications, that better distinguish monocyte lineages and responses in the brain from other types of myeloid cells may reveal points for therapeutic intervention, as well as a better understanding of ongoing inflammation associated with PD.